Emmaus Life Sciences, Inc. (EMMA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29137T1016

Price
0.02 USD
Market cap
1.61 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Emmaus Life Sciences, Inc. financials

Fiscal year2025
Revenue12.45 m USD
Gross profit11.60 m USD
Operating income231,000.00 USD
EBIT-349,000.00 USD
Net income-7.49 m USD
Diluted EPS – continuing operations-0.12 USD

Full history since 1999, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.